GSK (LON:GSK – Get Rating) received a GBX 1,300 ($14.97) price target from analysts at UBS Group in a research note issued on Friday, Borsen Zeitung reports. UBS Group’s target price would indicate a potential downside of 1.78% from the company’s current price.
Several other analysts also recently issued reports on GSK. Shore Capital reissued a “buy” rating on shares of GSK in a report on Wednesday, November 2nd. Berenberg Bank cut their price target on GSK from GBX 1,950 ($22.45) to GBX 1,580 ($18.19) and set a “buy” rating on the stock in a report on Wednesday, September 14th. Citigroup reissued a “neutral” rating and issued a GBX 1,975 ($22.74) price target on shares of GSK in a report on Thursday, July 21st. Barclays set a GBX 1,450 ($16.70) price target on GSK in a report on Wednesday. Finally, JPMorgan Chase & Co. cut their price target on GSK from GBX 1,900 ($21.88) to GBX 1,600 ($18.42) and set a “neutral” rating on the stock in a report on Tuesday, November 8th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, GSK presently has a consensus rating of “Hold” and an average target price of GBX 1,622 ($18.68).
GSK Trading Down 6.0 %
LON:GSK opened at GBX 1,323.60 ($15.24) on Friday. The company has a quick ratio of 0.73, a current ratio of 0.97 and a debt-to-equity ratio of 253.74. The business’s 50 day moving average is GBX 1,359.20 and its two-hundred day moving average is GBX 1,563.60. GSK has a 52 week low of GBX 1,280.92 ($14.75) and a 52 week high of GBX 2,746.59 ($31.62). The company has a market cap of £53.84 billion and a PE ratio of 1,214.31.
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn’t Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don’t Want to Get Stuck On
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.